STUDY OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE ENZYME AND ISOPROSTANE ON PREECLAMPSIA WITH NIFEDIPINE, METHYLDOPA, AND MAGNESIUM SULFATE THERAPY
Objective: The objective of this research is to measure erythrocyte glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and isoprostane and
to correlate enzyme activity of G6PD with proteinuria and isoprostane in pregnant with proteinuria after the administration of nifedipine, methyldopa,
and magnesium sulfate.
Methods: This cross-sectional study was held in Soewandi Hospital, Surabaya, East Java, Indonesia. This study used total sampling as much as 30
pregnant women with proteinuria who got nifedipine, methyldopa, and magnesium sulfate administration, age ranged from 17 to 48 years during their
third trimester (>20 weeks). G6PD enzyme activity was measured from plasma by spectrophotometric method; plasma isoprostane was measured
by competitive-ELISA method; and proteinuria urine spot was analyzed by urine dipstick from standardized laboratory of the hospital. Statistical
analysis used in this study was Spearman’s correlation coefficient.
Results: In this research, the effect of proteinuria +1 (OR=0.056) is lower than proteinuria +3 level on the presence of high G6PD enzyme activity,
and proteinuria +2 (OR=0.933) is lower than proteinuria +3 level on the presence of high G6PD enzyme activity in pregnant women with proteinuria.
G6PD enzyme was positively correlated (p=0.08) with proteinuria, and the connection was statistically significant. There was no significant statistic
correlation between G6PD enzyme activity and isoprostane concentration (p=0.797).
Conclusion: This study found correlations between the enzyme activity of G6PD and proteinuria as the marker of renal damage in pre-eclampsia (PE)
with the administration of nifedipine, methyldopa, and magnesium sulfate. However, it had no correlation with isoprostane as the marker of oxidative
stress. This study suggests that there should be a concern about understanding the pathophysiology of proteinuria for possibility of drug target for
individuals with PE.
pregnancy hypertension : An international journal of women ’s
cardiovascular health The classification, diagnosis and management
of the hypertensive disorders of pregnancy : A revised statement from
the ISSHP. Pregnancy Hypertens. Int J Women’s Cardiovasc Health
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO
analysis of causes of maternal death: A systematic review. Lancet
3. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R.
“Pre-eclampsia.” Lancet 2010;376:631-44.
4. Birawa AD, Hadisaputro H, Hadijono S. Kadar d-dimer pada ibu
hamil dengan preeklampsia berat dan normotensi di RSUP Dr. Kariadi.
Majalah Obstet. Ginekol Indones 2009;33:65-79.
5. Warih AP, Ernawati E, Susanti D. Characteristic of hellp syndrome in
severe preeclampsia patients in DR. soetomo hospital Surabaya. Folia
Medica Indonesiana 2013;51:272-6.
6. Schlembach D. Pre-eclampsia still a disease of theories. Fukushima J
Med Sci 2003;49:69-115.
7. Popovic J. Glucose-6-phosphate dehydrogenase deficiency and
pre-eclampsia: Possibility of treatment. Iran J Med Sci 2011;36:324.
8. Asgharnia M, Salamat F, Mirbolook F, Darabian B. Investigating
the relationship between glucose-6-phosphate dehydrogenase and
preeclampsia. Iran J Obstet Gynecol Infertil 2013;16:1-7.
9. Cappelini MC, Fiorelli G. Glucose-6-phosphate dehydrogenase
deficiency. Lancet 2008;371:64-74.
10. Faruky KS, Begum N, Begum S, Ali T, Ferdousi S, Amin AH. Study
of glucose-6-phosphate dehydrogenase (G6PD) status in preeclampsia.
BSMMU J 2009;2:56-60.
11. Kawamoto F, Matsuoka H, Kanbe T, Tantular IS, Pusarawati S,
Kerong HI, et al. Further investigations of glucose-6-phosphate
dehydrogenase variants in Flores Island, Eastern Indonesia. J Hum
12. Soemarno TM, Notopuro H, Santoso H. Glucose 6 phosphate
dehydrogenase (G6PD) deficiency in bad pregnancy history in st.
Vincentius a paulo catholic hospital, Surabaya. Folia Med Indones
13. Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, Lopez M.
Endothelial dysfunction and preeclampsia: Role of oxidative stress.
Front Physiol 2014;5:372.
14. Redman CW, Sargent IL. Circulating microparticles in normal
pregnancy and pre-eclampsia. Placenta 2008;29 Suppl A: S73-7.
15. Pereira RD, De Long NE, Wang RC, Yazdi FT, Holloway AC, Raha S.
Angiogenesis in the placenta: The role of reactive oxygen species
signaling. Biomed Res Int 2015;2015:12.
16. Ravarotto V, Simioni F, Pagnin E, Davis PA, Calò LA. Oxidative stress
chronic kidney disease cardiovascular disease: A vicious circle. Life Sci
17. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J,
Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation
in patients with moderate to severe chronic kidney disease. Kidney Int
18. Magee LA, CHIPS Study Group, von Dadelszen P, Singer J, Lee T,
Rey E, et al. Do labetalol and methyldopa have different effects on
pregnancy outcome? Analysis of data from the control of hypertension
in pregnancy study (CHIPS) trial. BJOG 2016;123:1143-51.
19. Smith P, Anthony J, Johanson R. Nifedipine in pregnancy. BJOG Int J
Obstet Gynaecol 2000;107:299-307.
20. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM,
et al. Oxidation of tetrahydrobiopterin leads to uncoupling of
endothelial cell nitric oxide synthase in hypertension. J Clin Invest
21. Carrière A, Carmona MC, Fernandez Y, Rigoulet M, Wenger RH,
Pénicaud L, et al. Mitochondrial reactive oxygen species control
the transcription factor CHOP-10/GADD153 and adipocyte
differentiation: A mechanism for hypoxia-dependent effect. J Biol
22. Castello PR, David PS, McClure T, Crook Z, Poyton RO. Mitochondrial
cytochrome oxidase produces nitric oxide under hypoxic conditions:
Implications for oxygen sensing and hypoxic signaling in eukaryotes.
Cell Metab 2006;3:277-87.
23. Wang CN, Chen JY, Sabu S, Chang YL, Chang SD, Kao CC, et al.
Elevated amniotic fluid F2-isoprostane: A potential predictive marker
for preeclampsia. Free Radic Biol Med 2011;50:1124-30.
This work is licensed under a Creative Commons Attribution 4.0 International License.